In this video

Share

This is a good deal for Celgene, says Bernstein senior analyst

Ronny Gal, Bernstein senior analyst, joins 'Power Lunch' to discuss the Celgene and Bristol-Myers merger.
03:03
Thu, Jan 3 20191:12 PM EST